文献速递骨肿瘤骨质疏松与代谢性骨病

识别非霍奇金淋巴瘤患者中治疗相关椎体密度丢失和骨折风险的研究

Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures.
PubMed 文献 · Osteoporos Int · 2020-08-15

本研究利用常规CT测量123例非霍奇金淋巴瘤(NHL)患者治疗前后L1-L3椎体密度,并与52例对照比较,发现NHL患者椎体密度丢失显著更大(P=0.003),且椎体密度丢失与偶发骨折风险相关(OR 1.90,95%CI 1.03-3.51,P=0.04),初始国际预后指数(IPI)为5的患者椎体密度丢失显著大于IPI为0者(P=0.01)。

要点

  • NHL患者治疗前后L1-L3椎体密度丢失显著大于对照组(P=0.003)。
  • 椎体密度每降低1个标准差,偶发骨折的OR为1.90(95%CI 1.03-3.51,P=0.04)。
  • 初始IPI为5的患者椎体密度丢失显著大于IPI为0者(P=0.01)。

核心结论

  • 使用常规CT进行椎体密度测量,可记录到NHL患者显著的椎体骨丢失,且骨折发生率高。

研究设计与样本

  • 研究纳入123例NHL患者,在2016年1月至2017年3月期间的常规CT扫描中测量L1、L2、L3椎体治疗前后的密度;对照测量(n=52)来自2003年9月至2017年9月期间的CT结肠成像及其后续随访检查(10-137个月)。
  • 采用线性回归模型比较患者与对照的椎体密度丢失并分析其与临床参数的关联,采用逻辑回归模型评估患者椎体密度每变化1个标准差对应的骨折OR,分析均校正年龄、性别和造影剂应用。

主要发现

  • NHL患者L1-L3椎体密度丢失显著大于对照组(P=0.003)。
  • L1-L3椎体密度丢失越大与偶发骨折可能性越高相关(OR 1.90,95%CI 1.03-3.51,P=0.04)。
  • 初始IPI为5的患者椎体密度丢失显著大于IPI为0者(P=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Information on bone loss in treated non-Hodgkin's lymphoma patients is limited. In this study, we used CT to analyze bone loss as well as prevalent and incident fractures. We found severe bone loss, a high rate of fractures, and a novel association between bone loss and the international prognostic index. INTRODUCTION: To investigate bone loss and fracture risk in non-Hodgkin-lymphoma (NHL) patients by (i) comparing treatment-related vertebral density (VD) loss in NHL patients with control subjects and (ii) investigating associations of VD loss versus fracture risk. Further, associations of VD loss and clinical parameters were investigated. METHODS: VD of 123 NHL patients was measured pre- and post-treatment in the L1, L2, and L3 vertebrae in routine computed tomography (CT) scans, performed between Jan 2016 and Mar 2017. Control measurements (n = 52) were obtained from CT colonographies between Sept 2003 and Sept 2017 and their subsequent follow-up-exams (10-137 months). Prevalent and incident (between baseline and follow-up) fractures were assessed in all subjects, and VD loss per year was calculated. Linear regression models were used to (i) compare VD loss between patients and controls and (ii) identify associations between VD loss and clinical parameters. Using logistic regression models, ORs for fractures per SD change in VD were assessed in patients. Analyses were adjusted for age, sex, and contrast application. RESULTS: NHL patients experienced significantly greater VDL1-3 loss than controls (P = 0.003), and greater VDL1-3 loss was associated with a greater likelihood of incident fractures (OR, [95%-CI], P 1.90, [1.03, 3.51], 0.04). Patients with an initial international prognostic index (IPI) of 5 suffered significantly greater VD loss compared with an IPI of 0 (P = 0.01). CONCLUSION: Using VD measurements in routine CT scans, substantial vertebral bone loss in NHL patients could be documented with a high incidence of fractures.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bodden J, Sun D, Joseph GB, et al. Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures. Osteoporos Int. 2020. PMID: 32803319. doi:10.1007/s00198-020-05577-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。